DBTX Projected Dividend Yield
Decibel Therapeutics Inc ( NASDAQ : DBTX )Decibel Therapeutics is a clinical-stage biotechnology company focused on discovering and developing transformative treatments for hearing and balance disorders. Co. is developing its primary gene therapy product candidate, DB-OTO, to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. In addition, Co. is advancing AAV.103 to restore hearing in individuals with mutations in the gap junction beta-2 gene and AAV.104 to restore hearing in individuals with mutations in the stereocilin gene. Co. is also developing DB-020 for the prevention of cisplatin-induced hearing loss, which it is evaluating in patients in a clinical trial. 20 YEAR PERFORMANCE RESULTS |
DBTX Dividend History Detail DBTX Dividend News DBTX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |